Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
VenBio
Biotech
Tumor-focused Parabilis raises $305M to 'upend status quo'
The biotech will harness the cash to advance FOG-001, recently named zolucatetide, towards a pivotal phase 3 trial in desmoid tumors.
Darren Incorvaia
Jan 8, 2026 7:00am
venBio raises $528M for fifth life sciences VC fund
Aug 1, 2024 12:30pm
Eyconis launches with $150M and Ascendis' eye disease meds
Jan 29, 2024 11:03am
Novartis-backed ImmPACT Bio gets $111M, ex-Pfizer exec for CEO
Jan 20, 2022 5:00am
BMS, VCs back Ceptur with $75M for RNA meds to silence pre-mRNA
Jan 19, 2022 7:00am
Ventyx files for $100M IPO to fund 6 or more trials by 2023
Sep 30, 2021 3:30pm
